

MARKET REPORT



Metastatic Uveal Melanoma - Pipeline Review, H2 2016

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Metastatic Uveal Melanoma - Pipeline Review, H2 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC8909IDB

Number of Pages : 56

Report Format : PDF

Publisher Information :



BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Metastatic Uveal Melanoma - Pipeline Review, H2 2016 [Published by Global Markets Direct]

- Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Uveal Melanoma Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Uveal Melanoma - Overview 7
Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8
Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9
Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 10
Metastatic Uveal Melanoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Uveal Melanoma - Products under Development by Companies 13
Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes 14
Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 15
Bellicum Pharmaceuticals Inc 15
Celldex Therapeutics Inc 16
Eli Lilly and Company 17
Novartis AG 18
Spectrum Pharmaceuticals Inc 19
Metastatic Uveal Melanoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
alpelisib - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BPX-701 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
emibetuzumab - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
glembatumumab vedotin - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
KCN-1 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
LXS-196 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
merestinib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
sotrastaurin acetate - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
vincristine sulfate - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Metastatic Uveal Melanoma - Dormant Projects 51
Metastatic Uveal Melanoma - Discontinued Products 52
Metastatic Uveal Melanoma - Product Development Milestones 53
Featured News & Press Releases 53
Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

How to Buy...

Metastatic Uveal Melanoma - Pipeline Review, H2 2016 [Published by Global Markets Direct]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/40046>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2000** | Single User Price
- \$4000** | Site License Price
- \$6000** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.